

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-13 (canceled).

14 (currently amended). A pharmaceutical composition comprising at least one CD23-binding peptide consisting of the amino acid sequence:

Phe-His-Glu-Asn-Trp-Pro-Ser (SEQ ID NO:1),

and dissolved in a pharmaceutically acceptable carrier.

15-57 (canceled).

58 (previously presented). The composition according to claim 14 wherein said peptide comprises at least one amino acid which is D-isomer.

59 (previously presented). A CD23-binding peptide, wherein said peptide consists of:

Phe-His-Glu-Phe-Trp-Pro-Thr (SEQ ID NO:2);

Phe-His-Ser-Gln-Trp-Pro-Asn (SEQ ID NO:3);

Phe-His-Glu-Asn-Trp-Pro (SEQ ID NO:4);

Phe-His-Glu-Asn-Trp-Pro-Thr (SEQ ID NO:5);

Phe-His-Glu-Gln-Trp-Pro-Ser (SEQ ID NO:6);

His-Glu-Asn-Trp-Pro-Ser	(SEQ ID NO:7);
His-Lvs-Asn-Trp-Pro-Ser	(SEQ ID NO:8);
His-Glu-Asn-Trp-Pro-Ser-Phe	(SEQ ID NO:9);
Phe-His-Lys-Pro-Trp-Arg-Ala	(SEQ ID NO:10);
His-Glu-Asn-Trp-Lys-Ser	(SEQ ID NO:31);
His-Glu-Asn-Trp-Xaa-Ser	(SEQ ID NO:32);
His-Glu-Asn-Trp-Gly-Ser	(SEQ ID NO:34);
His-Glu-Asn-Trp-Glu-Ser	(SEQ ID NO:35);
Phe-His-Glu-Ala-Trp-Pro-Ser	(SEQ ID NO:40);
Phe-His-Glu-Asn-Trp-Xaa-Ser	(SEQ ID NO:43);
His-Glu-Asn-Ala-Pro-Ser	(SEQ ID NO:53);
His-Glu-Asn-Trp-Ser	(SEQ ID NO:54);
G[allyl-] N W G[allyl-]	(SEQ ID NO:55);
NH ₂ Grallyl-] N W G[allyl-]	(SEQ ID NO:56);
Ac wn CO ₂ H	(SEQ ID NO:57);
Ac NW CO ₂ H	(SEQ ID NO:58);
Ac n w CO ₂ H	(SEQ ID NO:59);
Ac N W BetaA CO ₂ H	(SEQ ID NO:60); or
H E N W P CONH ₂	(SEQ ID NO:61).

60 (previously presented). The peptide according to claim 59 comprising at least one amino acid which is a D-isomer, an acylated N-terminus, and acetylated N-terminus or amidated C-terminus.

61 (previously presented). The composition according to Claim 14 wherein the N-terminus of said peptide is acylated.

62 (previously presented). The composition according to Claim 61 wherein the N-terminus of said peptide is acetylated.

63 (previously presented). The composition according to Claim 14 wherein the C-terminus of said peptide is amidated.

64 (currently amended). A peptide of ~~claim~~ Claim 59 wherein said peptide is labeled with a detectable marker.

65 (new). The peptide according to Claim 59 having a specific binding activity to CD23 of K_d = less than 10^{-6} M.

66 (new). The peptide according to Claim 40 wherein said peptide has a specific binding activity to CD23 of K_d comprised between at least about 10^{-6} and 10^{-11} M.